Recent studies' have established the presence of a factor ("activator," Coagulase-reacting factor, or CRF) in plasma which is required for the coagulation of blood by staphylocoagulase. Maximum CRF activity resides in the globulin fractions of plasma, and separation from prothrombin is best achieved by repeated Seitz filtration.10 The filtration involves different rates of adsorption of prothrombin and CRF," so that when the filtrate is essentially devoid of prothrombin it still may possess substantial CRF activity. Efforts to identify CRF with factors at present known to participate in physiological clotting of blood have been unsuccessful,10'11 and the hypothesis has been proposed that the coagulase-CRF reaction bypasses the currently accepted pathways functioning in physiological clotting. The many points of resemblance between prothrombin and CRF, as well as the differences, have been discussed elsewhere."11 Duthie and Lorenz' find it tempting to consider prothrombin and CRF as identical. They point to similarities in physical properties, parallel losses of both prothrombin and CRF when prothrombin is converted to thrombin, to localization in comparable fractions of plasma, and to the finding that the concentration of both prothrombin and CRF decrease "almost pari passu" following dicumarol administration in rabbits. To explain the separation of CRF from prothrombin by Seitz filtration, they suggest that this procedure may not actually remove prothrombin, but that the physical structure of prothrombin is so altered that it can no longer be converted to thrombin while it continues to function as a coagulase ''activator."
Recent studies' have established the presence of a factor ("activator," Coagulase-reacting factor, or CRF) in plasma which is required for the coagulation of blood by staphylocoagulase. Maximum CRF activity resides in the globulin fractions of plasma, and separation from prothrombin is best achieved by repeated Seitz filtration.10 The filtration involves different rates of adsorption of prothrombin and CRF," so that when the filtrate is essentially devoid of prothrombin it still may possess substantial CRF activity. Efforts to identify CRF with factors at present known to participate in physiological clotting of blood have been unsuccessful,10'11 and the hypothesis has been proposed that the coagulase-CRF reaction bypasses the currently accepted pathways functioning in physiological clotting. The many points of resemblance between prothrombin and CRF, as well as the differences, have been discussed elsewhere."11 Duthie and Lorenz' find it tempting to consider prothrombin and CRF as identical. They point to similarities in physical properties, parallel losses of both prothrombin and CRF when prothrombin is converted to thrombin, to localization in comparable fractions of plasma, and to the finding that the concentration of both prothrombin and CRF decrease "almost pari passu" following dicumarol administration in rabbits. To explain the separation of CRF from prothrombin by Seitz filtration, they suggest that this procedure may not actually remove prothrombin, but that the physical structure of prothrombin is so altered that it can no longer be converted to thrombin while it continues to function as a coagulase ''activator."
The observations of Duthie and Lorenz that dicumarol administration depresses CRF activity have been confirmed in this laboratory, both in rabbits and in patients undergoing dicumarol therapy for thrombotic disease. On the other hand, Miale' failed to note any effect on CRF levels of plasma of 21 patients on a dicumarol regime. The present study was 100% value. One-tenth ml. of the appropriate plasma dilutions were dispensed in 7 x 12 mm. pyrex tubes, 0.1 ml. of the prothrombin-free bovine plasma and 0.1 ml. of thromboplastin were added. After an incubation period of two minutes at 37°C., 0.1 ml. of 0.05 M CaCl2 was forcibly blown in with a 0.1 ml. serological pipette at the instant of setting the stop watch into motion. The tubes were observed under the same conditions as described above for CRF titration, and were gently tilted at room temperature to note the first appearance of fibrin. Except at the more prolonged clotting times, duplicate checks within two seconds were generally obtained. The test differed from the Ware and Stragnell technique in minor detail: the prothrombin-free bovine plasma was citrated rather than oxalated, and essentially freed of prothrombin by repeated Seitz filtration rather than by combined Seitz filtration and by barium sulfate adsorbtion. No heparin was added to the anticoagulant, but the higher concentration of citrate used to prevent the clotting of rabbit plasma necessitated the use of a higher concentration of calcium chloride.
Dicumarol (bishydroxycoumarin, Abbott). The tablets were ground in a mortar and pestle with propylene glycol1 to form a homogeneous suspension, and the drug was administered into the upper leg muscles of rabbits.
Phenylindanedione (PID)-obtained through the co6peration of Dr. E. A. Sharp and Dr. J. E. Gajewski of Parke, Davis and Co. was prepared and administered similarly to dicumarol.
Mephyton (Vitamin K1 Merck, 2-Methyl-3-phytyl-1,4-naphthoquinone). The emulsion, containing 50 mgm. per ml., was slowly administered intravenously, without untoward effect.
Rabbits. Adult domestically raised New Zealand white rabbits were used, ranging in weight from 3.09 to 5.02 kilograms.
RESULTS
The effect of dicumarol and of mephyton on CRF and on prothrombin of rabbits. In a preliminary titration (Table 1) 7 rabbits received intramuscularly dicumarol, rabbits #4, 5 and 12, 10 mgm./kg. and rabbits #3, 10, 11, and 14, 25 mgm./kg. It is readily apparent that dicumarol is effective in depressing both prothrombin and CRF. However, in most animals there was no close correspondence in the effects produced on prothrombin and on CRF, with the reduction in prothrombin being generally more rapid and severe than in CRF. Individual differences in the response of the rabbits overshadowed the dose of dicumarol administered, since there was no consistent increase in clotting times with the higher level of the drug. Rabbit #12 was unique in showing no reduction in CRF and only a minimal prothrombin effect, confirmed by a subsequent titration.
Since the preliminary titration did not reveal any close parallelism in dicumarol action on prothrombin and on CRF, it was deemed of interest to compare the response of these factors to a substance like mephyton known to combat the anticoagulant effect of dicumarol and similar agents. Accordingly, after a rest period of a month, rabbits #4, 5, 10, and 11 were given 25 mgm./kg. of dicumarol, and at 72 hours from 25 to 35 mgm. of mephyton were injected intravenously in rabbits #4, 5, and 10, respectively. The results are summarized in Table 2 , and expressed in both per cent of activity and in the actual clotting times obtained. Inspection of the data, especially when one compares the 144-hour post-dicumarol levels with those at the same time in Table 1 , clearly indicates the effectiveness of mephyton in reversing the dicumarol effect on CRF. The prothrombin titers, however, increased far more rapidly, and the apparent increase in prothrombin content was evident even within four hours following mephyton administration. The effect of phenylindanedione and of mephyton on CRF and prothrombin times in rabbits. Phenylindanedione (PID)4 '9 has recently been proposed as an anticoagulant which might reduce some of the hazards of dicumarol because of more rapid recovery after oral administration. It seemed of interest, therefore, to determine whether CRF is also affected by this drug, and whether this action is reversible by mephyton. Six rabbits were given PID intramuscularly in a dose of 75 mgm./kg. (Table 3 ). In spite of this excessive dose, parenterally administered, the reduction in prothrombin activity was not as drastic as with dicumarol, and by 60 hours, most of the animals were showing either rising titers or had returned to normal levels or beyond. The CRF reduction was not excessive either, was generally less marked than the prothrombin response, and was usually associated with a less rapid trend toward recovery at 60 hours. As in the experiments with dicumarol, rabbit #12 responded very poorly, with relatively slight action on prothrombin and on CRF alike. When mephyton was administered, in a dose of 40 mgm. per rabbit intravenously, prompt reversal of the anticoagulant effect of PID was noted (Table 4) . While the number of observations was too few to permit any generalization, and allowing for the differences in the 18-hour post-PID levels of prothrombin and CRF, a fairly close parallelism of action was evident. DISCUSSION
The data presented indicate that, like prothrombin, the coagulasereacting factor is depressed by the administration of dicumarol and of phenylindanedione. Similarly, Vitamin K1 (mephyton) effectively counteracts this depressing action on both prothrombin and CRF. If one adopts the view that these anticoagulants act by interfering with the synthesis of prothrombin in the liver from Vitamin K-like precursors, then these results may be interpreted as pointing to a structural similarity between the precursors of prothrombin and of CRF. The close relationship between prothrombin and CRF is further suggested by the response of rabbit #12. In this animal, both anticoagulants exerted minimal effects on prothrombin and on CRF alike.
In no sense, however, should these data be construed as implying an identity of structure of. prothrombin and of CRF. It has recently been shown that dicumarol has an effect also on prothrombin activators,2 hence its action cannot any longer be regarded as specifically interfering with prothrombin synthesis only. Even pari passu action of all the agents tested would not establish the identity of prothrombin and CRF, since this might represent similar action on closely related substances rather than on one factor. Actually, pari passu effects on prothrombin and on CRF were by no means consistently observed, even when allowances were made for differences in the sensitivity of the tests. On the contrary, frequently a sharp divergence in the prothrombin and CRF clotting times was observed. It is hoped that studies in progress on the chemical purification of CRF may yield more definitive data on the problem of its relation to prothrombin. SUMMARY A comparative study of the action of dicumarol and of phenylindanedione on the coagulase reacting factor and on prothrombin is presented.
Intramuscular administration of dicumarol and of PID in rabbits reduces the plasma levels of CRF as well as of prothrombin.
The response of CRF and of prothrombin to the anticoagulants does not consistently proceed pari passu.
Vitamin K1 (mephyton) successfully reverses the action of both anticoagulants on CRF and on prothrombin.
The implications of these observations on the problem of the relationship of CRF to prothrombin are discussed.
